Test Your Knowledge: ASCO 2020 Quiz
It’s no question that advancements in lung cancer treatment were in the spotlight at ASCO...
Sep 11, 2020
It’s no question that advancements in lung cancer treatment were in the spotlight at ASCO...
Jul 17, 2020
ASCO Lung Cancer Conference Reportv2.indd Download PDF Phase 3 CASPIAN Trial Update: Results &...
Jul 15, 2020
“The overall take home message from the Virtual ASCO Annual Meeting this year is that...
Jul 8, 2020
Results from the phase 2 Keynote-799 trial show that addition of pembrolizumab to concurrent chemoradiation in patients with unresectable, stage IIIA-C NSCLC leads to objective response rates (ORR) that exceeded 50%, researchers...
Jul 8, 2020
Phase 1 trial shows feasibility and safety of neoadjuvant and adjuvant atezolizumab with...
Jul 8, 2020
Long-term outcomes are still poor for patients with locally advanced NSCLC with about 60% of the...
Jul 8, 2020
MET-mutations and MET-amplifications are reported in 1-6% of patients with NSCLC. In a phase 2...
Jul 8, 2020
Adjuvant osimertinib demonstrated a statistically significant and clinically meaningful benefit...
Jun 26, 2020
A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being...
Jun 26, 2020
Targeting tumor driver appears effective in half of NSCLC patients Treatment with the...
Jun 23, 2020
Updated findings from the phase 3 CASPIAN trial presented at the 2020 American Society of Clinical...
Jun 23, 2020
In the phase 2 ECOG-ACRIN EA5161 trial, a significant improvement in both progression-free and overall survival was observed from adding the checkpoint inhibitor nivolumab to chemotherapy (cisplatin/carboplatin with etoposide)...